The presidency of the Committee for Coordination and Regional Development (CCDR) of the Algarve Region has just congratulated the scientist at the University of Algarve Clévio Nóbrega, for recognizing the research potential against Cockayne syndrome, a rare disease.
Clevio Nóbrega – principal investigator of the Algarve Biomedical Center – Academic Center for Biomedical Research and Training of the Algarve (ABC-RI) and professor at the Faculty of Medicine and Biomedical Sciences of the University of Algarve (UAlg) – has just received one million euros to develop a therapy against this rare and incurable disease, which mainly affects children, and which has a prevalence of around 2.7 per million births in Western Europe.
«CCDR ALGARVE salutes the University of Algarve for its permanent commitment to the Faculty of Medicine and Biomedical Sciences, for the support to its scientists and researchers, as well as for the work developed in cooperation with the Centro Hospitalar Universitário do Algarve (CHUA) within the framework of the Algarve Biomedical Center», reads in a press release.
According to the Coordinating Committee, with this funding, participants in the “CureCSB – Development of a Gene Therapy for Cockayne Syndrome Type B” project will develop, over the next two years, a gene therapy for Cockayne Syndrome, type B, which has the potential to reach the stage of clinical trials in the shortest possible time and can reach the clinical area in the near future, changing the lives of patients and their families.
To this end, the research group has specialists in the clinical and pharmaceutical fields.
Comments